m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00573)
Name
AZD1390
Synonyms
VQSZIPCGAGVRRP-UHFFFAOYSA-N; SCHEMBL18631972; AZD-1390; EX-A2670; CS-8217; 2089288-03-7; HY-109566
    Click to Show/Hide
Status
Phase 1
Structure
Formula
C27H32FN5O2
InChI
1S/C27H32FN5O2/c1-18(2)33-26-21-14-20(22(28)15-23(21)29-17-24(26)31(3)27(33)34)19-8-9-25(30-16-19)35-13-7-12-32-10-5-4-6-11-32/h8-9,14-18H,4-7,10-13H2,1-3H3
InChIKey
VQSZIPCGAGVRRP-UHFFFAOYSA-N
PubChem CID
126689157
TTD Drug ID
D0L6XO
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
ATM serine/threonine kinase (ATM)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary ATM serine/threonine kinase (ATM) is a therapeutic target for AZD1390. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD1390 through regulating the expression of ATM serine/threonine kinase (ATM). [1], [2]
References
Ref 1 N6-methyladenosine regulates ATM expression and downstream signaling. J Cancer. 2021 Oct 17;12(23):7041-7051. doi: 10.7150/jca.64061. eCollection 2021.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)